We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.
- Authors
Gómez-Dabó, Laura; Caronna, Edoardo; Mas-de-les-Valls, Rut; Gallardo, Víctor J.; Alpuente, Alicia; Torres-Ferrus, Marta; Pozo-Rosich, Patricia
- Abstract
Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days—MHD; monthly migraine days—MMD; acute medication days/month—AMDM) and side effect data were collected. A ≥ 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14.75–17], 70% (14/20) females). The median basal frequencies were 28.8 [20–28] MHD, 18 [10–28] MMD and 10 [7.5–21.2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of −20 days/month (p = 0.001). At 12 months (n = 14), eight patients (57.1%) were responders, with a median reduction in MHD of −17.5 days/month (p = 0.002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives.
- Subjects
SUMATRIPTAN; BOTULINUM A toxins; MIGRAINE; CHILD patients; TEENAGERS; NEURAL stimulation
- Publication
Toxins, 2024, Vol 16, Issue 5, p221
- ISSN
2072-6651
- Publication type
Article
- DOI
10.3390/toxins16050221